The yearly subscription-style payments made by NHS England to developers of novel antibiotics could be doubled from £10 million to £20 million in some cases, according to
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh